ADH 1

Drug Profile

ADH 1

Alternative Names: ADH-1; ADH-100001; Exherin

Latest Information Update: 23 Feb 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator McGill University
  • Developer Adherex Technologies
  • Class Antineoplastics; Cyclic peptides; Oligopeptides
  • Mechanism of Action Angiogenesis inhibitors; Cadherin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Solid tumours

Most Recent Events

  • 22 Apr 2009 Preclinical drug interactions data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 02 Jun 2008 Interim efficacy data from a phase I trial in Malignant melanoma released by Adherex Technologies
  • 19 May 2008 Interim efficacy data from a phase I/II trial in malignant melanoma released by Adherex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top